Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: The profit-J study

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 6, 2014, Pages 563-573

  Yoshii, Hidenori ^a   Onuma, Tomio ^a   Yamazaki, Tsutomu ^b   Watada, Hirotaka ^c   Matsuhisa, Munehide ^d   Matsumoto, Masayasu ^e   Kitagawa, Kazuo ^f   Kitakaze, Masafumi ^g   Yamasaki, Yoshimitsu ^f   Kawamori, Ryuzo ^c  

^a JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Diabetes mellitus; Mortality macrovascular events; Pioglitazone; Primary prevention

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PERIPHERAL EDEMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD PRESSURE; COMPARATIVE STUDY; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FOLLOW UP; METABOLISM; MIDDLE AGED; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84903184764     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.21626     Document Type: Article

References (29)

1. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E: Incidence and risk factors for stroke in type 2 diabetic patients: The DAI study. Stroke, 2007; 38: 1154-1160
2. Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE, Barnett HJ: The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American symptomatic carotid endarterectomy trial collaborators. N Engl J Med, 2000; 342: 1693-1700
3. Nomura K, Hamamoto Y, Takahara S, Kikuchi O, Honjo S, Ikeda H, Wada Y, Nabe K, Okumra R, Koshiyama H: Relationship between carotid intima-media thickness and silent cerebral infarction in Japanese subjects with type 2 diabetes. Diabetes Care, 2010; 33: 168-170
4. UK prospective diabetes study group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK prospective diabetes study (UKPDS) group. Lancet, 1998; 352: 837-853
5. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353: 2643-2653
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577-1589
7. Marso SP, Kennedy KF, House JA, McGuire DK: The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: A systematic review and meta-analysis. Diab Vasc Dis Res, 2010; 7: 119-130
8. Glass CK, Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophage and T cells. Nat Rev Immunol, 2010; 10: 365-376
9. Li AC, Brown KK, Silvestre MJ, Wilson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclereosis in LDL receptor-deficient mice. J Clin Invest, 2000; 106: 523-531
10. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007; 356: 2457-2471
11. Schernthaner G, Chilton RJ: Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes Metab, 2010; 12: 1023-1035
12. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007; 298: 1180-1188
13. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 2006; 296: 2572-2581
14. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from proactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke, 2007; 38: 865-873
15. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H: Committee on the standardization of diabetes mellitus-related laboratory testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to national glycohemoglobin standardization program values. Diabetol Int, 2012; 3: 8-10
16. Sasaki M, Ida M, Yamada K, Watanabe Y, Matsui M: Standardizing display conditions of diffusion-weighted images using concurrent b0 images: A multi-vendor multiinstitutional study. Magn Reson Med Sci, 2007; 6: 133-137
17. Yamasaki Y, Katakami N, Furukado S, Kitagawa K, Nagatsuka K, Kashiwagi A, Daida H, Kawamori R, Kaku K: Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb, 2010; 17: 1132-1140
18. The Japan Diabetes Society: Treatment Guide for Diabetes 2007 Edited by the editorial committee members of "Treatment Guide for Diabetes" Bunkodo Co., Ltd., Tokyo, Japan 2007
19. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T: Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes, 1996: 45 Suppl 3: S14-16
20. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993; 16: 434-444
21. Yamasaki Y, Nakajima K, Kusuoka H, Izumi T, Kashiwagi A, Kawamori R, Shimamoto K, Yamada N, Nishimura T: Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes: The J-access 2 investigation. Diabetes Care, 2010; 33: 2320-2326
22. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y: Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA, 2008; 300: 2134-2141
23. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest, 1995; 96: 354-360
24. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2005; 28: 1547-1554
25. Ferrannini E, Betteridge DJ, Dormandy JA, Charbonnel B, Wilcox RG, Spanheimer R, Erdmann E, Defronzo RA, Laakso M. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes Obes Metab. 2011; 13: 759-764
26. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA: Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care, 2008; 31: 1672-1678
27. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J: Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clin ical trial in macrovascular events): A randomised controlled trial. Lancet, 2005; 366: 1279-1289
28. UK prospective diabetes study group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet, 1998; 352: 854-865
29. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J, 2004; 25: 10-16